ALK and non-small cell lung carcinoma: Brigatinib (Alunbrig, AP26113) is a multi-kinase inhibitor of ALK, ROS1, FLT3, mutant variants of FLT3, and also T790M-mutant EGFR [155], approved by the FDA as a treatment against anaplastic lymphoma kinase (ALK)-positive metastatic NSCLC [156].